EXENT™ system resource library

Clinical case reports, peer-reviewed studies, podcasts and educational materials on mass spectrometry-based M-protein detection. Use the filters below to browse the library of evidence.

Featured resources

 

View all resources

Featured resources
Accurate diagnoses for patients with low-level m-protein in AL amyloidosis
Accurate diagnoses for patients with low-level m-protein in AL amyloidosis
See how the EXENT GAM assays identified an IgGλ M-protein at 2.42 g/L in an AL amyloidosis patient when SPE and IFE were both negative. Clinical case study with expert podcast.
Explore AL case study
Therapeutic antibody profiling in multiple myeloma using MALDI-ToF mass spectrometry
Therapeutic antibody profiling in multiple myeloma using MALDI-ToF mass spectrometry
Read antibody research
Mass spectrometry in multiple myeloma: predicting progression-free survival
Mass spectrometry in multiple myeloma: predicting progression-free survival
Read survival research

EXENT system clinical evidence for monoclonal gammopathy assessment

The EXENT system , comprising of the EXENT™ analyzer and EXENT™ GAM assay is supported by a growing body of clinical evidence. The resources below bring together clinical case reports, peer-reviewed studies, and expert commentary from laboratories using mass spectrometry in monoclonal gammopathy workflows.

Published data and clinical experience across these resources examine:

  • Detection of low-level M-proteins below the reporting limits of electrophoresis-based methods
  • Resolution of therapeutic antibody and oligoclonal-band interference
  • Earlier identification of biochemical relapse and disease progression
  • Serial quantitative monitoring and clonal tracking over time

For background on the conditions these resources address, see monoclonal gammopathies and multiple myeloma in Clinical Applications.

All resources

Filter resources by content type, disease state, or author to find the evidence and educational materials most relevant to your needs.

Uncovering m-proteins within the β region
Uncovering m-proteins within the β region
See how EXENT GAM assays quantified IgA M-protein missed by SPE in the beta region. 1.52 g/L identified. Download the full case study.
Read β region case study
Therapeutic antibody profiling in multiple myeloma using MALDI-ToF mass spectrometry
Therapeutic antibody profiling in multiple myeloma using MALDI-ToF mass spectrometry
Learn how intact MALDI-ToF mass spectrometry identifies therapeutic antibodies in multiple myeloma, with reference m/z values for 14 profiled monoclonal antibodies.
Read antibody research
Sensitivity beyond complete response
Sensitivity beyond complete response
See how EXENT GAM assays detected residual M-protein in ~45% of myeloma patients in conventional complete response. Download the full case study.
View survival research
Resolving oligoclonal banding and therapeutic antibody interference
Resolving oligoclonal banding and therapeutic antibody interference
See how EXENT GAM assays resolved M-protein ambiguity from oligoclonal banding and therapeutic antibody interference. 84% concordance with IFE. Download the full case study.
View antibody profiling
New perspectives on monoclonal proteins
New perspectives on monoclonal proteins
See how EXENT GAM assays detects M-protein glycosylation in MGUS patients. 67% with glycosylated light chains progressed to malignancy. Download the case study.
Read interference study
Monoclonal gammopathies: MALDI-TOF mass spectrometry clinical guidelines
Monoclonal gammopathies: MALDI-TOF mass spectrometry clinical guidelines
SEMEDLAB-SEHH guidelines endorse MALDI-TOF mass spectrometry for M-protein detection and monitoring in monoclonal gammopathies. Learn more from The Binding Site.
View clinical guidelines
Mass spectrometry in multiple myeloma: predicting progression-free survival
Mass spectrometry in multiple myeloma: predicting progression-free survival
Serum mass spectrometry assessment in multiple myeloma predicts progression-free survival. Learn more from The Binding Site.
Read survival research
Mass spectrometry before MRD testing in myeloma: EXENT system budget impact from France and Spain
Mass spectrometry before MRD testing in myeloma: EXENT system budget impact from France and Spain
Two 2025 budget impact analyses show using mass spectrometry before MRD testing in myeloma cuts procedures and costs. Learn more from The Binding Site.
View budget analysis
Identifying biochemical relapse earlier
Identifying biochemical relapse earlier
See how the EXENT GAM assays detected M-protein re-emergence four months before SPE in a patient with multiple myeloma. Download the full case study.
Read relapse case study
Accurate diagnoses for patients with low-level m-protein in AL amyloidosis
Accurate diagnoses for patients with low-level m-protein in AL amyloidosis
See how the EXENT GAM assays identified an IgGλ M-protein at 2.42 g/L in an AL amyloidosis patient when SPE and IFE were both negative. Clinical case study with expert podcast.
Explore AL case study

Ready to bring the EXENT system into your lab?

The EXENT system delivers mass spectrometry-based detection of monoclonal proteins with a level of sensitivity and specificity that conventional technologies cannot match. Talk to our specialists to learn more about platform specifications, workflow, assay methodology and intended uses.

Request a consultation
Explore the EXENT system

Get notified when new evidence is published
New case reports, publications, and educational materials are added to this library regularly. Subscribe to be notified.